Psyence BioMed partner produces high-purity ibogaine extract

Psyence Biomedical Ltd. (NASDAQ: PBM) announced that its strategic partner PsyLabs has produced a GMP-aligned ibogaine total alkaloid extract that meets microbial safety standards for food-grade consumption, according to verification by an accredited third-party laboratory.

The extract represents progress in PsyLabs' development of psychedelic active pharmaceutical ingredients. Psyence BioMed acquired an equity stake in PsyLabs in 2024 and continued its investment in 2025.

"This is a groundbreaking moment for our entire team on the ground who have put countless hours and effort into ensuring our naturally derived, sustainable input materials are extracted with the same caution, mindfulness, and care, all covering the GMP manufacturing processes," said Cody Robyn Futeran, Head of Extraction Innovations and Business Development at PsyLabs.

PsyLabs CEO Tony Budden said the company is committed to refining processes to achieve higher purity levels to support demand for psychedelic APIs. The company is expanding its chemistry production area to meet demand for ibogaine HCL, psilocybin isolate, and other compounds derived from iboga and mushrooms.

PsyLabs operates from an ISO 22000-certified facility and holds federal licenses to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine. The company has exported psilocybin products to Canada, the UK, Portugal, and Slovenia.

The ibogaine will be available to licensed research institutions and developers worldwide. Information is based on a company press release.

You May Also Be Interested In

• DMB stockholders back incumbent board, reject Saba's nominee
• Agilent launches compact Cary 635 FTIR spectrometer
• Los Andes Copper Announces Election to Issue Common Shares in Satisfaction of US$9 Million Convertible Debenture Interest Payment Obligations